

Community-acquired pneumonia – Still a Major Burden of Disease

Charles Feldman MB BCh, DSC, PhD, FRCP, FCP (SA)

Professor of Pulmonology and Chief Physician, Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (charles.feldman@wits.ac.za Tel: +27 11 488-3840).

Ronald Anderson PhD

Research Professor, Institute for Cellular and Molecular Medicine, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa (ronald.anderson@up.ac.za Tel:+27 12 319-2425).

Address and Correspondence:

Professor Charles Feldman
Department of Internal Medicine
Faculty of Health Sciences
University of the Witwatersrand Medical School
7 York Road,
Parktown, 2193
Johannesburg,
South Africa
Tel 011 488-3840
Fax 011 488-4675

Abstract

Purpose of review: Describe recent studies that may impact on the management of community-acquired pneumonia (CAP).

Recent findings: CAP continues to be associated with a considerable burden of disease. Diagnosis remains problematic, and various biomarkers are neither accurate in the diagnosis of the presence of CAP nor are superior to standard severity of illness scores in predicting outcome. Current evidence indicates that patients with non-severe CAP can be effectively treated with antibiotic monotherapy, while those with severe infection, particularly ICU cases, do best with early initiation of combination antibiotic therapy. Several studies have investigated anti-inflammatory, adjunctive therapies for severe CAP, with corticosteroids appearing to be most promising. It is well recognized that cardiac complications occur during the course of CAP, being associated with poorer short-term and long-term outcomes, prompting considerable interest in the adjunctive potential of statins and anti-platelet therapies. In addition to evaluating these adjunctive therapies, attention has also focused on identifying strategies that predict the need for ICU admission in patients with CAP.

Summary: While questions remain, particularly with regard to prediction of outcome, recent studies of CAP, both clinical and experimental, have contributed novel insights into disease pathogenesis which may enable improvement of current treatment strategies.

Keywords: adjunctive therapy, antibiotics, cardiac complications, community-acquired pneumonia, intensive care unit

Introduction

Community-acquired pneumonia (CAP) is associated with a large burden of disease throughout the world, causing considerable morbidity and mortality and generating substantial healthcare costs. This article will review some of the major studies that have been undertaken in the previous 12 months describing various aspects of CAP.

CAP burden of Disease

Recent studies from the United States (US) [1^a,2], Europe [3,4] and Asia [5,6] attest to the considerable burden of community-acquired pneumonia (CAP) in these regions of the world. One US study of adults hospitalized for CAP in Chicago and Nashville documented the annual incidence to be 24.8 cases (95% CI, 23.5-26.1) per 10,000 adults with significant and progressively higher rates in the elderly and the very elderly [1]. A second US study documented the burden of CAP in the US Veterans Health Administration (VHA) [2]. The median age of the CAP patients was 65 years, with the majority of patients over the age of 50 years, and especially those 65 years of age and older, having one or more chronic medical conditions (considered moderate risk) or immunocompromising conditions (considered high risk) predisposing to CAP [2]. The relative risk of CAP in these patients was >3 times and > 6 times greater, respectively, than in healthy adults. One year mortality rates varied between 1% and 36%, the latter being in high-risk cases \geq 65 years of age. The annual CAP expenditure for the VHA was estimated at \$750 million.

A retrospective study in the Netherlands estimated the incidence of CAP to be 295 per 100,000 population per year [3]. Of the 195,372 cases, 63% were hospitalized and 5.9% admitted to the intensive care unit (ICU) for at least one night. The total

cost for these CAP episodes over the 4 year period of study was estimated at Euro 711 million [3]. Interestingly, in Oxfordshire in the United Kingdom (UK), one study documented that the incidence of CAP increased 4.2% per year between 1998 and 2008 and 8.8% per year between 2009 and 2014 [4].

A study from Japan estimated the incidence of CAP in patients aged ≥ 15 years to be 16.9/1000 patient-years (PY), with a rate of hospitalization of 5.3/1000 PY and in-hospital mortality of 0.7/1000 PY [5]. The incidence rates were much higher with increasing age, being 10-fold higher in those ≥ 85 years compared with non-elderly adults. Another study from Japan documented that greater severity of disease, need for mechanical ventilation and tube feeding were associated with higher hospitalization costs [6].

In all the studies described above in which microbiological data were collected, *Streptococcus pneumoniae* was one of the most common, if not the commonest, cause of CAP [1,4,5].

Diagnosis of the presence of CAP

A number of interesting studies have been undertaken regarding the documentation of the presence or absence of CAP in patients suspected of having such an infection [7[■],8[■]]. In one study, patients suspected of having CAP, and having had a chest radiograph, underwent a multidetector computerised tomographic (CT) scan of the chest [7[■]]. The study documented that the use of a CT scan markedly affected both the diagnosis of CAP and its subsequent clinical management. The same authors documented, furthermore, that in patients with a gold standard diagnosis of CAP,

which included the use of CT scan of the chest, measurement of C-reactive protein (CRP) and procalcitonin (PCT) levels were not sufficient to confirm the CAP diagnosis or to distinguish bacterial from viral CAP [8[■]].

Cardiac complications of CAP

There is increasing awareness of the possible occurrence of cardiovascular complications in patients with CAP. Corrales-Medina and colleagues [9] noted that hospitalization for pneumonia was associated with an increased risk for new-onset heart failure and suggested that further research should investigate the possible mechanisms, in order to try and prevent its occurrence. These same authors confirmed that hospitalization for pneumonia was a risk factor for both short-term and long-term risk of cardiovascular disease [10]. Cangemi and colleagues [11[■]] also documented that the occurrence of cardiac complications early during hospitalization for CAP was associated not only with an increased risk of death in the patients, but also with the occurrence of additional cardiovascular events during long-term follow-up. Aliberti and co-workers [12[■]] noted that there were differences in the outcome of CAP patients having an acute myocardial infarction (AMI) as a cardiac complication versus those having another type of cardiovascular event (CVE). In those with AMI, the in-hospital mortality was 43% versus 21% in those with another CVE ($p=0.039$) (OR for in-hospital mortality with AMI 3.57 ($p=0.012$) versus 2.63 ($p=0.002$) for CVE) [12[■]]. Brown and colleagues undertook a comprehensive review of the mechanisms of cardiotoxicity that occurs during invasive pneumococcal disease [13[■]].

Empiric antibiotic treatment for CAP

There is still considerable debate as to the appropriate antibiotic therapy for patients with CAP in the different settings (outpatient, inpatient, ICU), as well as the impact of early initiation of antibiotic treatment. One recent systematic review documented that in hospitalized patients with CAP, initiation of antibiotic therapy with a beta-lactam/macrolide combination or fluoroquinolone monotherapy within 4-8 hours of hospital arrival was associated with a lower adjusted short-term mortality [14[■]]. It was noted that this was supported mainly by low-quality observational studies. However, a second systematic review of randomized controlled trials, although on this occasion including both outpatients and inpatients, and therefore including a larger number of less severely ill patients, concluded that there was no benefit of beta-lactam/macrolide or beta-lactam/fluoroquinolone therapy over fluoroquinolone monotherapy alone [15]. In a cluster-randomized crossover trial, Postma and colleagues documented that beta-lactam monotherapy was non-inferior to beta-lactam/macrolide combination or fluoroquinolone monotherapy [16]. There were a number of considerations with regard to this study, not least of which being the fact that the patients were largely not severely ill cases, as evidenced by the median CURB-65 score of 1 (IQR 1-2) and mean PSI score of below 90 for each of the patient groups, both scores indicating the presence of mainly lower-risk patients [16].

In contrast, Gattarello and colleagues [17[■]] undertook a matched case control study of patients with non-pneumococcal, severe CAP and concluded from the multivariate analysis that combined antibiotic therapy (OR 0.23; 95% CI, 0.07 – 0.74) and early antibiotic treatment (OR 0.07; 95% CI, 0.02-0.22) were associated with a superior ICU survival. These same authors undertook a review of the published literature on

antibiotic treatment of CAP since 2005 and concluded that combination therapy, mainly beta-lactam/macrolide therapy, is associated with a lower mortality in CAP patients requiring ICU admission, and is associated with better outcome, although not always mortality, in non-ICU with poor prognostic factors, in patients with bacteremic pneumococcal pneumonia, and in patients suspected of having infections with atypical pathogens [18].

In this regard it is interesting to note a recent study that documented that patients with bacteremic pneumococcal CAP had higher in-hospital mortality, lower time to clinical stability and longer length of hospital stay, which was also associated with high levels of biomarkers and systemic cytokine levels than in non-bacteremic patients [19]. Ye et al [20] also suggested that in hospitalized patients with CAP, covering for atypical pathogens with appropriate antibiotic treatment, was associated with a lower mortality and economic burden. Sibila and colleagues [21], while documenting that in *P. aeruginosa* CAP appropriate empiric antibiotic therapy in the first 48 hours was associated with lower 30-day mortality, also noted that current guideline recommended risk factors for predicting pseudomonal CAP, allowed the detection of only a third of cases [21].

Two recent studies were published on behalf of the British Thoracic Society which included data on time of administration of antibiotics in patients with CAP [22[■],23]. In one study, a quality improvement program was instituted in which CAP care bundles were implemented [22[■]]. Analysis of the data indicated that significantly more patients received an antibiotic within 4 hours of admission (adjusted OR 1.52; 95% CI, 1.08-2.14; p=0.016) and there was a lower 30-day mortality (8.8% versus 13.6%;

adjusted OR 0.59; 95% CI, 0.37-0.95; p=0.03). The authors concluded that the study indicated that implementation of these care bundles was feasible and although time to antibiotic administration was a key process measure, the improvement in mortality could not be attributed to it alone [22[■]]. Another matched-propensity analysis of patients with CAP noted that time to receipt of first antibiotic (TFA) was 4 hours or less in 63% of cases and adjusted 30-day in-patient mortality was lower in those patients in which TFA was ≤ 4 hours versus those in which TFA was >4 hours [23]. However, the authors concluded that while this association was found, it was difficult to determine whether it was causal or not. This aspect of antibiotic administration in patients with CAP needs further study.

Adjunctive therapies in CAP

Four categories of pharmacological agents have attracted considerable attention as potential adjunctive anti-inflammatory therapies to beta-lactam antibiotics in the treatment of CAP. These are macrolide antimicrobial agents, corticosteroids, statins and anti-platelet therapies.

Macrolides

As discussed above, macrolides are an important component of the antibiotic treatment strategies of patients with severe CAP. It is considered by many that these benefits are not purely because of their antimicrobial activity, but also because of their considerable adjuvant properties which have been attributed to: i) inhibition of synthesis of bacterial virulence factors, counteracting the pro-inflammatory and cytotoxic potential of bactericidal antibiotics which promote disintegration of bacterial pathogens with release of toxins such as pneumolysin (Ply) in the case of the pneumococcus; and ii) the secondary, anti-inflammatory immunomodulatory

properties of these agents which target various types of immune and structural cells and their inflammatory mediators [24, 25].

Corticosteroids

The apparent benefit of adjunctive corticosteroid therapy in the clinical setting of hospitalized patients with severe CAP is supported by the recent systematic review and meta-analysis reported by Siemieniuk *et al.* [26²²]. This analysis included all randomized trials of systemic corticosteroids in hospitalized adults, predominantly elderly, with CAP (a total of 13 trials encompassing 2005 patients). The authors documented significant reductions in: i) time to clinical stability and duration of hospital stay (high quality evidence for both); and ii) reductions in the requirement for mechanical ventilation, as well as the occurrence of acute respiratory distress syndrome (moderate quality evidence for both) [26²²]. Significantly lower mortality was evident only in the sub-group of patients with most severe disease [26²²]. While commending Siemieniuk and colleagues, subsequent commentaries raised several caveats, most importantly the need to identify sub-groups of patients which would benefit most from adjunctive therapy with corticosteroids [27–29], possibly those with the highest systemic biomarker inflammatory indices [30] and/or those with shock requiring vasopressor support [31]. These issues may be resolved on completion of several ongoing clinical trials [29].

Statins

Statins are widely-used, lipid-lowering drugs used in the therapy and prevention of cardiovascular disorders. These agents target the enzyme, 3-hydroxy-3-methyl-glutaryl CoA reductase, inhibiting the synthesis of both cholesterol and isoprenoids,

activities which are also of potential benefit in the anti-inflammatory, adjunctive therapy of CAP [reviewed in 32]. In the case of the former, decreasing the cholesterol content of the plasma membranes of inflammatory/immune and structural cells counteracts the cytotoxic and pro-inflammatory activities of the cholesterol-binding, pore-forming toxin, pneumolysin [33]. In the latter scenario, defective isoprenylation compromises signaling mechanisms involving G-protein-coupled receptors (GPCRs) on immune/inflammatory cells and platelets, attenuating the pro-inflammatory activities of these cells.

Although a number of observational studies have reported improved survival of patients with CAP receiving prior treatment for pre-existing cardiovascular conditions [32], only one prospective controlled trial has assessed the benefit of statins administered at the time of hospitalization to patients with CAP [34]. This was a small study in which 19 and 15 patients were randomized to receive 20mg simvastatin or placebo respectively, administered within the first 24 hours of hospital admission and daily for 4 days thereafter. However, adjunctive therapy with the statin did not result in either significant clinical benefit or reductions in systemic inflammatory indices [34]. In addition to those identified by the authors, other limitations of this trial include: i) insufficient numbers of patients for sub-group analysis, specifically those with pneumococcal CAP who may benefit most from statin adjunctive therapy; and ii) the absence of baseline measurement of biomarkers such as CRP and PCT [34].

Despite their broad-ranging anti-inflammatory and pneumolysin-targeting potential, the promise of statin therapy in pneumococcal CAP remains unproven and dependent on the outcome of large carefully-controlled, prospective, multicenter,

clinical trials. Given the increased risk for development of fatal cardiac disease for up to 5 years following recovery from CAP [11,24] these should include assessment of the preventive potential of statins administered during the extended recovery period.

Anti-platelet agents

Notwithstanding their pro-thrombotic potential, platelets are now well recognized as being key players in orchestrating inflammatory responses particularly those involving neutrophils [35]. If poorly regulated, however, these pro-thrombotic/pro-inflammatory activities pose the risk of organ damage and dysfunction as illustrated by the findings of 2 recent studies. In the first of these, Cangemi *et al.* reported that the occurrence of acute cardiac events in hospitalized patients with CAP is associated with increased concentrations of biomarkers consistent with systemic activation of platelets [36[■]]. More recently, Claushuis *et al.* reported that patients admitted to ICU with severe sepsis who had “very low” ($<50 \times 10^9/L$) or “intermediate-low” ($50\text{--}99 \times 10^9/L$) blood platelet counts had significantly higher mortality rates [hazard ratios (HRs) of 2.0 and 1.72 respectively] relative to those with “low” ($100\text{--}149 \times 10^9/L$) or normal ($150\text{--}399 \times 10^9/L$) counts [37[■]]. Severe thrombocytopenia, also consistent with systemic activation of platelets, was associated with increased levels of plasma cytokines, enhanced endothelial activation, and impaired vascular integrity [37[■]].

The apparent involvement of platelets in the pathogenesis of pulmonary and cardiac injury, as well as multiple organ dysfunction syndrome, in patients with severe CAP, has ignited considerable interest in the adjunctive potential of anti-platelet therapies [32]. To date, however, no published studies have addressed the issue of anti-

platelet therapy administered at the time of diagnosis of CAP. The closest at present is the study reported by Falcone *et al.* comparing the 30-day mortality rates of hospitalized patients with CAP (n=1005, age 74.7±15.1 years, 390 of whom were receiving aspirin therapy (100 mg/day) at the time of admission [38¹¹]. The authors reported a HR for total mortality of 2.07 ($P=0.029$) in the aspirin-free group, as well as an overall frequency of non-fatal cardiovascular events of 7%, accounting for respective rates of 8.3% and 4.9% in the aspirin-free and –treated groups (odds ratio = 1.77, $P<0.04$ [38¹¹].

An ongoing phase I, placebo-controlled, intervention trial, which includes hospitalized patients with CAP and hospital-acquired pneumonia, is focused primarily on the effects of administration of the P2Y₁₂ receptor antagonist, ticagrelor, on the levels of circulating biomarkers of platelet activation, including platelet/neutrophil aggregates, and their association with acute lung injury and lung mechanics [39]. Other outcome measures include the occurrence of major CVEs and 30-day mortality [39].

ICU admission and management for CAP

With regard to predictors of ICU admission in patients with CAP, one study documented that severity of illness, as documented by PSI class IV (OR 3.06; 95% CI, 1.63-5.72), PSI class V (OR 4.84; 95% CI, 2.44-9.62), CURB-65 ≥ 3 (OR 2.90; 95% CI, 1.51-5.56) and presence of underlying chronic obstructive pulmonary disease (COPD)(34.7% versus 19.1% among patients not admitted to ICU) were important factors [40]. The latter is an interesting observation, since a systematic review and meta-analysis indicated that COPD does not appear to be associated

with more frequent ICU admission (RR 0.97; 95% CI, 0.70-1.35; $p=0.87$), need for mechanical ventilation (RR 0.91; 95% CI, 0.71-1.16; $p=0.44$), or greater mortality in hospitalized patients with CAP (RR 1.20; 95% CI, 0.92-1.56; $p=0.19$) in cohort studies, but a reduced mortality in case-control studies (RR 0.82; 95% CI, 0.74-0.90; $p<0.0001$) [41]. A recent, but largely unexplored, strategy advocates the potential utility of blood gene expression microarray analysis to identify gene signatures which distinguish CAP from non-CAP patients on admission to ICU [42].

-

While one Spanish single center study [43] documented that despite a higher incidence and severity of severe CAP, the crude ICU mortality decreased by 18%, possibly due to increased use of combination antibiotic therapy, another secondary data analysis from the CAPO multicentre study database [44] suggested that the mortality of severe CAP has increased over three time periods between 2001 and 2013. There continues to be much debate regarding whether the current modified IDSA/ATS minor criteria for severe CAP are appropriate or could be modified to provide a more accurate mortality prediction and, if so, which combination of criteria were most suitable [45[■], 46]. The CAPNETZ Study Group investigated the entity called “emergency CAP”, being a group of CAP patients requiring need for early mechanical ventilation and/or need for vasopressor use and having a high mortality [47[■]]. They noted that abnormalities of vital signs and parameters indicating end organ dysfunction were important and that the ATS/IDSA minor criteria showed a high negative predictive value [47[■]].

A study by Murad and colleagues [48] suggested that non-invasive ventilation (NIV) in patients with CAP was associated with a high failure rate, and mortality was not

improved in a group of patients that were suggested, on clinical characteristics, to be suitable for NIV; nevertheless this study generated considerable further debate in the literature and the authors acknowledged that the findings need to be more comprehensively delineated in further randomized studies. The findings of the study by Hifumi and colleagues [49] in elderly patients with CAP suggested that age alone should not be a limiting factor in the initiation of mechanical ventilation for CAP in the emergency department and future studies should attempt to determine appropriate indications for ventilation of patients of advanced age.

Sjoding and colleagues [50[■]] documented that hospitals that had the highest rate of ICU admissions for elderly patients with pneumonia were much less likely to deliver the appropriate pneumonia processes of care and that the patients had a worse outcome. The authors suggested that such hospitals may benefit from appropriate interventions.

Prognosis and outcome of CAP

Weir and colleagues [51] noted that the presence of multimorbidity was associated with worse short-term prognosis in patients with CAP, and suggested that these factors should be considered when making site-of care decisions in CAP patients presenting to the emergency department and in discharge decisions of CAP patients from hospital. Interestingly, severe thinness ($BMI < 16 \text{ kg/m}^2$) is associated with increased 30-day mortality in patients with CAP, such that nutritional status needs to be considered in mortality prediction in patients with CAP [52[■]]. In contrast, Eurich and colleagues [53[■]] undertook a study in which patients presenting to hospital with radiologically-confirmed CAP, and treated according to a validated clinical pathway,

were compared with regard to various long-term outcomes to 5 control subjects without CAP who were age, sex and site of treatment matched. The study documented that the CAP patients were at high risk of long-term adverse events, irrespective of age.

Biomarkers

Measurement of various circulating host-derived, inflammatory biomarkers is of potential value in prediction of disease severity and outcome. Of these, CRP and PCT are the two which have been most actively researched, with PCT in particular being useful in guiding antibiotic therapy [54]. However, a recently published systematic review and meta-analysis concluded that neither CRP nor PCT, nor a number of other biomarkers of disease severity and cardiac injury, including midregional proadrenomedullin, copeptin, prohormone forms of atrial natriuretic peptide and cortisol, were superior to PSI and CURB-65 in the prediction of CAP-related mortality [55[■]].

Other systemic biomarkers of interest include lactate, cardiac troponins and other cardiac biomarkers, vitamin D, high density lipoproteins, mean platelet volume, red blood cell distribution width, lysophosphatidylcholine, soluble ST2, various cytokines, serum pregnancy-associated plasma protein A, and various others, which are too numerous to be described or referenced in this short review. Prioritizing the clinical utility of these many and increasing diagnostic and predictive procedures based on the detection of host-, as well as pathogen-derived, biomarkers represents a considerable challenge in the management of severe CAP.

Conclusions

Recent studies have documented that CAP is still associated with a considerable burden of disease, and high healthcare costs. Diagnosis of CAP remains problematic and biomarkers such as CRP and PCT have limited ability to confirm the presence of CAP and these, as well as various other biomarkers, are not superior to standard severity of illness scores at prognosticating in patients with CAP. Overall evidence is that while non-severe CAP can safely be treated with antibiotic monotherapy, patients with severe infection, particularly those requiring ICU admission, do best with the early initiation of combination antibiotic therapy. There have been a number of recent studies investigating adjunctive therapies for severe CAP, with studies on corticosteroids appearing most promising. It is now well recognised that cardiac complications occur during the course of CAP and are associated with poorer short-term and long-term outcomes. Much recent work has investigated factors that help predict the need for ICU admission and various aspects of ICU care for patients with CAP.

Key points

- Community-acquired pneumonia is still associated with a considerable burden of disease and substantial healthcare costs.
- The diagnosis of the presence of community-acquired pneumonia still remains problematic on clinical grounds.
- Cardiac events are now well documented to occur in patients with community-acquired pneumonia and are associated with considerable short and long-term mortality.

- In severely ill patients with community-acquired pneumonia, the early initiation of combination antibiotic treatment appears to be associated with the best outcome.
- Various forms of adjunctive therapy have been studied for use in severely ill patients with community-acquired pneumonia, of which corticosteroids currently appear to be most common

Acknowledgements: Charles Feldman is supported by the National Research Foundation of South Africa

Conflict of interest: Charles Feldman has acted on the advisory board and/or speakers bureau of pharmaceutical companies manufacturing or marketing macrolide antibiotics (Abbott, Aspen, Pfizer, Sandoz). Ronald Anderson has no conflict of interest to declare

References

1. Jain S, Self WH, Wunderink RG, et al., for the CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373(5): 415 – 427.
An active population-based surveillance study in adults (≥ 18 years) hospitalized with CAP in five hospitals in Chicago and Nashville, which undertook comprehensive microbiological testing in the patients, documented the incidence of CAP in this region, which was highest among the oldest adults, and noted that a pathogen was not documented in the majority of patients.

2. McLaughlin JM, Johnson MH, Kagan SA, Baer SL. Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011; a retrospective cohort study. *Infection* 2015; 43: 671 – 680.
3. Rozenbaum MH, Mangen M-JJ, Huijts SM, et al. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. *Vaccine* 2015; 33: 3193 – 3199.
4. Quan TP, Fawcett NJ, Wrightson JM, et al., on behalf of the Infections in Oxfordshire Research Database (IORD). Increasing burden of community-acquired pneumonia leading to hospitalisation, 1998-2014. *Thorax* 2016 [E-pub ahead of print]. doi: 10.1136/thoraxjnl-2015-207688.
5. Morimoto K, Suzuki M, Ishifulji T, et al., Adult Pneumonia Study Group – Japan (APSG-J). The burden and etiology of community-onset pneumonia in the aging Japanese population: A multicenter prospective study. *PLoS ONE* 2015; 10(3): e0122247.
6. Uematsu H, Kunisawa S, Yamashita K, Imanaka Y. The impact of patient profiles and procedures on hospitalization costs through length of stay in community-acquired pneumonia patients based on a Japanese administrative database. *PLoS ONE* 2015; 10(4): e0125284.
7. Claessens Y-E, Debray M-P, Tubach F et al. Early computed tomography scan to assist in diagnosis and guide treatment decision for suspected community-acquired pneumonia, *Am J Respir Crit Care Med* 2015; 192: 974-982.

This was a prospective, multicenter interventional study that documented that in patients with suspected CAP who had had a chest radiograph (CXR), chest CT findings markedly affected the diagnosis and treatment. CT scan documented an

infiltrate in 40 (33%) of patients without infiltrate on CXR and excluded CAP in 56 (29.8%) of those with an infiltrate on CXR. On the basis of the CT scan, antibiotics were initiated in 51 (16%) and discontinued in 29 (9%) and hospitalisation was decided in 22 and discharge in 23.

8. ■■Le Bel J, Hausfater P, Chenevier-Gobeaux C, et al. Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having systematic thoracic CT scan. *Critical Care* 2015; 19: 366.

In an ancillary investigation to the CT scan study described above, measurement of CRP and PCT in patients with CAP, using the CT scan as a gold standard, were found not to be adequate to confirm the diagnosis of CAP.

9. Corrales-Medina VF, Taljaard M, Yende S, et al. Intermediate and long-term risk of new-onset heart failure after hospitalization for pneumonia in elderly adults. *Am Heart J* 2015; 170: 306 – 312.

10. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk cardiovascular disease. *JAMA* 2015; 313(3): 264 – 274.

11. ■■Cangemi R, Calvieri C, Falcone M, et al., in collaboration with the SIXTUS Study Group. Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascular events. *Am J Cardiol* 2015; 116: 647 – 651.

This was a prospective study of adults hospitalized with CAP in which it was documented that the occurrence of in-hospital cardiovascular events during the early phase of pneumonia are associated with an increased risk of death as well as the occurrence of cardiovascular events during long-term follow-up.

12. ■Aliberti S, Ramirez J, Cosentini R, et al. Acute myocardial infarction *versus* other cardiovascular events in community-acquired pneumonia. ERJ Open Res 2015; 1:00020-2015. doi: 10.1183/23120541.00020-2015.

This was an international, prospective, multicenter study that documented that in patients with CAP, the mortality was significantly greater in those patients that suffered an acute myocardial infarction compared with those that had other types of cardiovascular events

13. ■■Brown AO, Millett ERC, Quint JK, Orihuela CJ. Cardiotoxicity during invasive pneumococcal disease. Am J Respir Crit Care Med 2015; 191(7): 739 – 745.

This excellent review describes the mechanisms of cardiotoxicity that occur during invasive pneumococcal disease. Important host-pathogen interactions that have been noted to occur include; pneumococcal cell wall-mediated inhibition of cardiomyocyte contractility, which is platelet-activating factor dependent; translocation of pneumococci into the myocardium forming discrete, non-purulent microscopic lesions; cardiomyocyte cell death most likely as a consequence of pneumolysin and hydrogen peroxide activity. Understanding of these pathogenic mechanisms may lead to novel forms of treatment and/or prevention of pneumococcal infections.

14. ■Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia. A systematic review. JAMA 2016; 315(6): 593 – 602.

This was a systematic review of antibiotic therapy in hospitalized adults with CAP that documented that early initiation of antibiotic therapy consisting of a combination of a β -lactam and a macrolide or fluoroquinolone monotherapy was

associated with lower-adjusted short-term mortality, albeit supported mainly by low-quality, observational studies.

15. Raz-Pasteur A, Shasha D, Paul M. Fluoroquinolones or macrolides alone versus combined with β -lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. *Int J Antimicrob Agents* 2015; 46: 242 – 248.
16. Postma DF, van Werkhoven CH, van Elden LJR, et al., for the CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. *N Engl Med J* 2015; 372(14): 1312 – 1323.
17. Gattarello S., Lagunes L, Vidaur L, et al. Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case- control study. *Critical Care* 2015: 19: 335.

This was a matched case-control study investigating patients with severe non-pneumococcal CAP, that noted that both early administration of antibiotics and combination antibiotic therapy were associated with increased intensive care unit survival.
18. Gatterello S. What is new in antibiotic therapy in community-acquired pneumonia? An evidence-based approach focusing on combined therapy. *Curr Infect Dis Rep* 2015; 17: 45.
19. Bordon JM, Fernandez-Botran R, Wiemken TL, et al. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response. *Infection* 2015; 43: 729 – 738.
20. Ye X, Ma J, Hu B, et al. Improvement in clinical and economic outcomes with empiric antibiotic therapy covering atypical pathogens for community-acquired

pneumonia patients: a multicenter cohort study. *Int J Infect Dis* 2015; 40: 102 – 107.

21. Sibila O, Laserna E, Maselli DJ, et al. Risk factors and antibiotic therapy in *P.aeruginosa* community-acquired pneumonia. *Respirology* 2015; 20: 660 – 666.

22. ■Lim WS, Rodrigo C, Turner AM, et al., on behalf of the British Thoracic Society. British Thoracic Society community-acquired pneumonia care bundle: results of a national implementation project. *Thorax* 2016; 71: 288 – 290.

This study documented the feasibility of implementing a CAP care bundle in 16 UK hospital trusts as part of a quality improvement project and demonstrated that in the bundle-implementation group, more patients received antibiotics within 4 hours of admission and 30-day in-hospital mortality was lower, although the latter could not be attributed to early antibiotic administration alone.

23. Daniel P, Rodrigo C, McKeever TM, et al. Time to first antibiotic and mortality in adults hospitalized with community-acquired pneumonia: A matched-propensity analysis. *Thorax* 2015 [E-pub ahead of print]. doi: 10.1016/j.ajhg.2015.11.001.

24. Bender MT, Niederman MS. Improving outcomes in community-acquired pneumonia. *Curr Opin Pulm Med* 2016; 22:235–242.

25. Emmet O'Brien M, Restrepo MI, Martin-Loeches I. Update on the combination effect of macrolide antibiotics in community-acquired pneumonia. *Respir Investig* 2015; 53:201–209.

26. ■■Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: A systematic review and meta-analysis. *Ann Intern Med* 2015; 163:519–528.

This is the most comprehensive systematic review and meta-analysis to date

addressing the potential of corticosteroids in the adjunctive therapy of severe CAP.

27. Waterer G. Systemic corticosteroids and community-acquired pneumonia – cautious optimism or wishful thinking? *J Thorac Dis* 2015; 7:E622–E624.
28. Wunderink RG. Corticosteroids for severe community-acquired pneumonia: not for everyone. *JAMA* 2015; 313:673–674.
29. Feldman C, Anderson R. Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. *J Thorac Dis* 2016 [Early on-line at <http://dx.doi.org/10.3978/j.issn.2072-1439.2016.02.43>].
30. Restrepo MI, Anzueto A, Torres A. Corticosteroids for severe community-acquired pneumonia: time to change clinical practice. *Ann Intern Med* 2015; 163:560–561.
31. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. *Eur Respir J* 2015; 45:463–472.
32. Feldman C, Anderson R. Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies. *Chest* 2015; 148:523–532.
33. Statt S, Ruan JW, Hung LY, et al. Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells. *Am J Respir Cell Mol Biol* 2015; 53:689–702.
34. Viasus D, Garcia-Vidal C, Simonetti AF, et al. The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. *BMJ Open* 2015; 4:e006251.

35. Mauler M, Seyfert J, Haenel D, et al. Platelet-neutrophil complex formation – a detailed *in vitro* analysis of murine and human blood samples. J Leukoc Biol 2015 [Epub ahead of print].

36. ■■Cangemi R, Casciaro M, Rossi E, et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol 2014; 64:1917–1925.

These authors documented the association between increased levels of systemic biomarkers of platelet activation and the development of acute cardiovascular events in hospitalized patients with CAP.

37. ■Claushuis TA, van Vught LA, Scicluna BP, et al. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. Blood 2016 [Epub ahead of print].

The authors of this study documented the relationship between the severity of thrombocytopenia on admission to ICU and mortality in patients with severe sepsis.

38. ■■Falcone M, Russo A, Cangemi R, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am heart Assoc 2015; 4:e001595.

The only publication to date demonstrating that aspirin therapy, albeit pre-existing as opposed to interventional, protects against the development of acute cardiovascular events and mortality in hospitalized CAP patients.

39. U.S. National Institutes of Health. Targeting platelet-leukocyte aggregates in pneumonia with ticagrelor (XANTHIPPE). ClinicalTrials.gov: NCT01883869. Last updated December 4, 2015. Accessed on March 3, 2016. Available from: <https://clinicaltrials.gov/ct2/show/NCT01883869>.

40. Vohra AS, Tak HJ, Shah MB et al. Intensive care unit admission with community-acquired pneumonia. *Am J Med Sci* 2015; 350: 380-386.
41. Jiang H-L, Chen H-X, Liu W, et al. Is COPD associated with increased mortality and morbidity in hospitalized pneumonia? A systematic review and meta-analysis. *Respirology* 2015; 20: 1046-1054.
42. Scicluna BP, Klein Klouwenberg PM, van Vught LA, et al. A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission. *Am J Respir Crit Care Med* 2015; 192:826–835.
43. Valles J, Diaz E, Martin-Loeches I, et al. Evolution over a 15-year period of the clinical characteristics and outcomes of critically ill patients with severe community-acquired pneumonia. *Med Intensiva* 2015; pii: S0210-5691(15)00164-3.
44. Cavallazi R, Wiemken T, Arnold FW, et al. Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. *Respiratory Medicine* 2015; 109: 743-750.
45. Li H-Y, Guo Q, Song W-D, et al. Modified IDSA/ATS criteria for severe community-acquired pneumonia best predicted mortality. *Medicine* 2015; 94: e1474.
- This study documented that the IDSA/ATS minor criteria for severe CAP could be simplified to 5 variables and then be modified to orchestrate improvements in predicting mortality in severe CAP.
46. Li H-Y, Guo Q, Song W-D, et al. Mortality among severe community-acquired pneumonia patients depends on combinations of 2007 IDSA/ATS minor criteria. *Int J Infect Dis* 2015; 38: 141-145.

47. Kolditz M, Ewig S, Klapdor B, et al., on behalf of the CAPNETZ study group. Community-acquired pneumonia as medical emergency: predictors of early deterioration. *Thorax* 2015; 70: 551-558.
- This study characterized those patients with CAP who had the poorest short-term prognosis in order to facilitate early identification and improved management of these patients.
48. Murad A, Li PZ, Dial S, Shahin J. The role of noninvasive positive pressure ventilation in community-acquired pneumonia. *J Crit Care* 2015; 30: 49-54.
49. Hifumi T, Jinbo I, Okada I, et al. The impact of age on outcomes of elderly ED patients ventilated due to community-acquired pneumonia. *Am J Emerg Med* 2015; 33: 277-281.
50. Sjoding MW, Prescott HC, Wunsch H, et al. Hospitals with the highest intensive care utilization provide lower quality pneumonia care to the elderly. *Crit Care Med* 2015; 43: 1178-1186.
- This retrospective cohort study documented that among hospitals with the highest rates of ICU admission for elderly patients, quality of care was lowest; such hospitals were less likely to deliver pneumonia processes of care, and the outcomes for pneumonia among the patients was poorer.
51. Weir DL, Majumdar SR, McAlister FA, et al. The impact of multimorbidity on short-term events in patients with community-acquired pneumonia: prospective cohort study. *Clin Microbiol Infect* 2015; 21: e7-264. e13.
52. Lee J, Kim K, Jo YH, et al. Severe thinness is associated with mortality in patients with community-acquired pneumonia: a prospective observational study. *Am J Emerg Med* 2015; 33: 209-213.

An interesting study documented that severe thinness ($\text{BMI} \leq 16\text{kg/m}^2$) was associated with higher 30-day mortality in patients with CAP.

53. ■Eurich DT, Marrie T, Minhas-Sandhu JK, Majumdar SR. Ten-year mortality after community-acquired pneumonia, A prospective cohort. *Am J Respir Crit Care Med* 2015; 192: 597-604.

A study documenting that an episode of CAP was associated with a high risk of long-term adverse events compared with patients who have not had an episode of CAP.

54. Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. *Lancet* 2015; 386:1097–1108.

55. ■■Viasus D, Del Rio-Pertuz G, Simonetti AF, et al. Biomarkers for predicting short term mortality in community-acquired pneumonia: a systematic review and meta-analysis. *J Infect* 2016; 72:273–282.

This study, while conceding moderate-to-good accuracy of a range of host-derived, systemic biomarkers of inflammation in predicting outcome in patients with severe CAP concluded that these were not superior to established clinical scoring systems.